Rhythm Pharmaceuticals Stock (NASDAQ: RYTM)

Rhythm Pharmaceuticals (NASDAQ:RYTM) Stock, Quote.Headers.trade-ideas

Rhythm Pharmaceuticals

Rhythm Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in development and commercialization of therapies for patients with rare diseases. It is focused on the development and commercialization of peptide therapeutics for the treatment of gastrointestinal, or GI, diseases, and genetic deficiencies that result in metabolic disorders. The company's product candidate is setmelanotide (RM 493), which is a potent, melanocortin 4, or MC4, receptor agonist for the treatment of rare genetic disorders of obesity caused by MC4 pathway deficiencies. Geographically the company generates its revenue from the United states, Germany, and other with the majority being generated from the United states.

jim-cramer_shutterstock2

ASPN

ENVX

LRCX

MRVL

RYTM

VALE

The &#34;Mad Money&#34; host recommended buying some Marvell Technology, and then wait until under $60 to buy the rest.

Jim Cramer Is &#39;Willing To Let This Pharma Stock Catch Fire,&#39; Advises Not To Sell McKesson

Biotech

Equities

News

Health Care

Markets

General

During the R&amp;D event for investors, Rhythm Pharmaceuticals Inc (NASDAQ: RYTM) released new topline data from its Phase 3 pediatrics trial evaluating one year of setmelanotide in patients aged two and below six years with Bardet-Biedl syndrome (BBS) or proopiomelanocortin (POMC) or leptin recep

Rare Genetic Diseases Of Obesity-Focused Rhythm Pharma&#39;s Bardet-Biedl Syndrome Drug Meets Primary Goal In Pediatric Trial

Penny Stocks

Small Cap

Intraday Update

Movers

Trading Ideas

ABVC

ADMP

AMSC

ANET

ARQQ

AUDC

AURC

BRSH

CJET

CONNEXA SPORTS TECH INC by Connexa Sports Technologies Inc.

CNXA

CYBN

EQRX

EXFY

FOXO

FWAC

GLDD

HLIT

HUBC

IDAI

INVO

IPGP

JBLU

LIDR

LTRY

MATV

MGAM

MODV

MSGM

NCLH

NKLA

OKYO

PLOW

PTRA

QUBT

RGTI

RMBS

RVMD

SILV

SOFI

TGTX

UFCS

VRNS

YELL

YUMC

ZBRA

ZENV

Gainers


	Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) shares gained 188.8% to $4.13. The stock is now on the Regulation SHO &#34;threshold security&#34; list.


Why Aaron&#39;s Shares Are Trading Lower By Over 9%? Here Are Other Stocks Moving In Tuesday&#39;s Mid-Day Session

Rhythm Pharmaceuticals, Inc. - Common Stock

Rhythm Pharmaceuticals Inc

During the last three months, 4 analysts shared their evaluations of Rhythm Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RYTM#NASDAQ">RYTM</a>), revealing diverse outlooks from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Rhythm Pharmaceuticals and provided 12-month price targets. The average target is $59.5, accompanied by a high estimate of $64.00 and a low estimate of $55.00. Surpassing the previous average price target of $50.50, the current average has increased by 17.82%.
<img src="https://www.benzinga.com/files/images/story/2024/1726664419_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The standing of Rhythm Pharmaceuticals among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Announces</td>
<td>Buy</td>
<td>$64.00</td>
<td>-</td>
</tr>
<tr>
<td>Jonathan Wolleben</td>
<td>JMP Securities</td>
<td>Announces</td>
<td>Market Outperform</td>
<td>$64.00</td>
<td>-</td>
</tr>
<tr>
<td>Joseph Stringer</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$55.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Joseph Stringer</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$55.00</td>
<td>$46.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Rhythm Pharmaceuticals. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Rhythm Pharmaceuticals compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Rhythm Pharmaceuticals's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Rhythm Pharmaceuticals's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/RYTM/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Rhythm Pharmaceuticals analyst ratings.</a>
<h2>Get to Know Rhythm Pharmaceuticals Better</h2>
Rhythm Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in development and commercialization of therapies for patients with rare diseases. It is focused on the development and commercialization of peptide therapeutics for the treatment of gastrointestinal, or GI, diseases, and genetic deficiencies that result in metabolic disorders. The company's product candidate is setmelanotide (RM 493), which is a potent, melanocortin 4, or MC4, receptor agonist for the treatment of rare genetic disorders of obesity caused by MC4 pathway deficiencies. Geographically the company generates its revenue from the United states, Germany, and other with the majority being generated from the United states.
<h3>Rhythm Pharmaceuticals's Financial Performance</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: Rhythm Pharmaceuticals displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately 51.28%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Rhythm Pharmaceuticals's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -115.42% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Rhythm Pharmaceuticals's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -66.51%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Rhythm Pharmaceuticals's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -10.48%, the company may face hurdles in achieving optimal financial returns.
Debt Management: With a below-average debt-to-equity ratio of 0.1, Rhythm Pharmaceuticals adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

What 4 Analyst Ratings Have To Say About Rhythm Pharmaceuticals

HC Wainwright &amp; Co. analyst Raghuram Selvaraju initiates coverage on Rhythm Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RYTM#NASDAQ">RYTM</a>) with a Buy rating and announces Price Target of $64.

Price Target

Initiation

HC Wainwright & Co. Initiates Coverage On Rhythm Pharmaceuticals with Buy Rating, Announces Price Target of $64

WIIM

Rhythm Pharmaceuticals shares are trading higher after JMP Securities initiated coverage on the stock with a Market Outperform rating and announced a price target of $64.

JMP Securities analyst Jonathan Wolleben initiates coverage on Rhythm Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RYTM#NASDAQ">RYTM</a>) with a Market Outperform rating and announces Price Target of $64.

JMP Securities Initiates Coverage On Rhythm Pharmaceuticals with Market Outperform Rating, Announces Price Target of $64

Rhythm Pharmaceutical shares are trading higher after the company announced FDA acceptance for priority review of supplemental NDA for IMCIVREE.

-- Label expansion sought to treat younger children with Bardet-Biedl syndrome or POMC/LEPR deficiency -- &nbsp;
-- FDA sets PDUFA goal date of December 26, 2024 --
BOSTON, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RYTM#NASDAQ">RYTM</a>), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's supplemental New Drug Application (sNDA) for IMCIVREE&#xAE; (setmelanotide), a melanocortin-4 receptor (MC4R) agonist, for the treatment of obesity due to Bardet-Biedl syndrome (BBS) or pro-opiomelanocortin (POMC), including proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency obesity in children as young as 2 years old. The FDA has granted Priority Review of the sNDA and assigned a Prescription Drug User Fee Act (PDUFA) goal date of December 26, 2024.&nbsp;

Rhythm Pharmaceuticals Announces FDA Acceptance For Priority Review Of Supplemental NDA For IMCIVREE In Patients As Young As 2 Years Old

Needham analyst Joseph Stringer reiterates Rhythm Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RYTM#NASDAQ">RYTM</a>) with a Buy and maintains $55 price target.

Reiteration

Needham Reiterates Buy on Rhythm Pharmaceuticals, Maintains $55 Price Target

For the year ending December 31, 2024, Rhythm anticipates approximately&nbsp;$250 million&nbsp;to&nbsp;$270 million&nbsp;in Non-GAAP Operating Expenses.&nbsp;

Guidance

Rhythm Pharmaceuticals Says Cash On-hand Expected To Support Planned Operations Into 2026

Rhythm Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RYTM#NASDAQ">RYTM</a>) reported quarterly losses of $(0.55) per share which beat the analyst consensus estimate of $(0.71) by 22.54 percent. This is a 32.93 percent increase over losses of $(0.82) per share from the same period last year. The company reported quarterly sales of $29.078 million which beat the analyst consensus estimate of $28.789 million by 1.00 percent. This is a 51.28 percent increase over sales of $19.221 million the same period last year.

Earnings

Earnings Beats

Rhythm Pharmaceuticals Q2 2024 GAAP EPS $(0.55) Beats $(0.71) Estimate, Sales $29.078M Beat $28.789M Estimate

Rhythm Pharmaceuticals Announces European Commission Expansion Of IMCIVREE Marketing Authorization To Include Children Aged 2-5 With Obesity Due To Bardet Biedl Syndrome Or POMC, PCSK1, And LEPR Deficiency

Rhythm Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RYTM#NASDAQ">RYTM</a>) has been analyzed by 4 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Rhythm Pharmaceuticals, presenting an average target of $55.5, a high estimate of $79.00, and a low estimate of $42.00. This current average represents a 1.33% decrease from the previous average price target of $56.25. 
<img src="https://www.benzinga.com/files/images/story/2024/1721908871_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
A comprehensive examination of how financial experts perceive Rhythm Pharmaceuticals is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joseph Stringer</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$55.00</td>
<td>$46.00</td>
</tr>
<tr>
<td>Whitney Ijem</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Buy</td>
<td>$79.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Tazeen Ahmad</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$42.00</td>
<td>$49.00</td>
</tr>
<tr>
<td>Joseph Stringer</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$46.00</td>
<td>$50.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Rhythm Pharmaceuticals. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Rhythm Pharmaceuticals compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
To gain a panoramic view of Rhythm Pharmaceuticals's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/RYTM/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Rhythm Pharmaceuticals analyst ratings.</a>
<h2>About Rhythm Pharmaceuticals</h2>
Rhythm Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in development and commercialization of therapies for patients with rare diseases. It is focused on the development and commercialization of peptide therapeutics for the treatment of gastrointestinal, or GI, diseases, and genetic deficiencies that result in metabolic disorders. The company's product candidate is setmelanotide (RM 493), which is a potent, melanocortin 4, or MC4, receptor agonist for the treatment of rare genetic disorders of obesity caused by MC4 pathway deficiencies. Geographically the company generates its revenue from the United states, Germany, and other with the majority being generated from the United states.
<h3>Rhythm Pharmaceuticals: A Financial Overview</h3>
Market Capitalization: Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.
Revenue Growth: Over the 3 months period, Rhythm Pharmaceuticals showcased positive performance, achieving a revenue growth rate of 126.41% as of 31 March, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Rhythm Pharmaceuticals's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -544.43% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Rhythm Pharmaceuticals's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -122.22%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Rhythm Pharmaceuticals's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -47.81%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: With a below-average debt-to-equity ratio of 0.02, Rhythm Pharmaceuticals adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Significance of Analyst Ratings Explained</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Glimpse Into The Expert Outlook On Rhythm Pharmaceuticals Through 4 Analysts

Needham analyst Joseph Stringer maintains Rhythm Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RYTM#NASDAQ">RYTM</a>) with a Buy and raises the price target from $46 to $55.

Needham Maintains Buy on Rhythm Pharmaceuticals, Raises Price Target to $55

-- LB54640 has shown targeted effect on MC4R without hyperpigmentation&nbsp;-- &nbsp;
BOSTON, July 23, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RYTM#NASDAQ">RYTM</a>), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, today announced that the first patients have been dosed in the Company's Phase 2 clinical trial evaluating LB54640, an investigational oral melanocortin-4 receptor (MC4R) agonist, in hypothalamic obesity.

Rhythm Pharmaceuticals First Patients Dosed In Phase 2 Trial Evaluating Oral MC4R Agonist LB54640 In Hypothalamic Obesity

The European Medicines Agency&#39;s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the marketing authorization for IMCIVREE&nbsp;(setmelanotide) include children between 2 and younger than 6 years old with obesity due to Bardet Biedl syndrome (BBS) or pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency.

Rhythm Says European Medicines Agency's CHMP Adopted Positive Opinion Recommending Marketing Authorization For IMCIVREE; European Commission Decision Anticipated In H2 Of 2024

Including Options For 9,230 Shares And RSUs For 46,850 Shares

Rhythm Pharmaceuticals Grants Inducement Equity Covering 56,080 Shares To Ten New Employees

- Participants from the completed Phase 2 hypothalamic obesity trial reported positive changes in sleep, energy levels during setmelanotide therapy in qualitative interviews&nbsp;
- Separate analysis of patients across MC4R pathway diseases showed one year of treatment with setmelanotide improved NIH, WHO weight classifications -
- Previously reported stage one results from Phase 2 DAYBREAK trial showed potential setmelanotide efficacy in multiple MC4R pathway variants; stage two data expected in Q3 2024 -
- Preclinical data demonstrated potential of RM-718 to reduce body weight and hunger -
- Additional posters feature design of Phase 1 trial of RM-718 and real-world RESTORE study -

Rhythm Pharmaceuticals Presents First Patient And Caregiver Reported Experiences From Phase 2 Trial Of Setmelanotide In Hypothalamic Obesity At ENDO 2024

Rhythm Pharmaceuticals Announced That The National Institute For Health And Care Excellence Issued Guidance That Recommends Imcivree (setmelanotide) As An Option For Treatment Of Obesity And Hyperphagia In Patients With Bardet-biedl Syndrome

Canaccord Genuity analyst Whitney Ijem maintains Rhythm Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RYTM#NASDAQ">RYTM</a>) with a Buy and lowers the price target from $80 to $79.

Canaccord Genuity Maintains Buy on Rhythm Pharmaceuticals, Lowers Price Target to $79

B of A Securities analyst Tazeen Ahmad downgrades Rhythm Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RYTM#NASDAQ">RYTM</a>) from Buy to Neutral and lowers the price target from $49 to $42.

Downgrades

B of A Securities Downgrades Rhythm Pharmaceuticals to Neutral, Lowers Price Target to $42

Needham analyst Joseph Stringer maintains Rhythm Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RYTM#NASDAQ">RYTM</a>) with a Buy and lowers the price target from $50 to $46.

Needham Maintains Buy on Rhythm Pharmaceuticals, Lowers Price Target to $46

In a report released today, Joseph Stringer from Needham reiterated a Buy rating on Rhythm Pharmaceuticals (RYTM – Research Report), with a price t...

Buy Rating Reaffirmed for Rhythm Pharmaceuticals Amid Strong Imcivree Sales and Promising Clinical Trials

Ladenburg Thalmann & Co. analyst Michael Higgins maintained a Buy rating on Rhythm Pharmaceuticals (RYTM – Research Report) today and set a price t...

Strong Financial Health and Expanding Market Presence Solidify Buy Rating for Rhythm Pharmaceuticals

Canaccord Genuity analyst Whitney Ijem maintained a Buy rating on Rhythm Pharmaceuticals (RYTM – Research Report) yesterday and set a price target ...

Buy Rating Reaffirmed for Rhythm Pharmaceuticals Amid Strong Q2 Performance and Promising Pipeline

Morgan Stanley analyst Jeffrey Hung maintained a Buy rating on Rhythm Pharmaceuticals (RYTM – Research Report) today and set a price target of $55....

Morgan Stanley Sticks to Their Buy Rating for Rhythm Pharmaceuticals (RYTM)

Wells Fargo analyst Derek Archila maintained a Buy rating on Rhythm Pharmaceuticals (RYTM – Research Report) today and set a price target of $53.00...

Wells Fargo Keeps Their Buy Rating on Rhythm Pharmaceuticals (RYTM)

FDA sets target action date for Rhythm's sNDA for Imcivree

Rhythm: Pivotal Moment Approaching In Hypothalamic Obesity (Rating Upgrade)

Tracking Baker Brothers Portfolio - Q2 2024 Update

Rhythm Pharmaceuticals (RYTM) has received a new Buy rating, initiated by JMP Securities analyst, Jonathan Wolleben. Jonathan Wolleben has given hi...

Buy Rating Affirmed for Rhythm Pharmaceuticals Amid Strong Market Position and Promising Pipeline

Rhythm Pharma draws bullish view at JMP on opportunity in rare genetic obesities

ABBV

ABCL

ACAD

AKRO

ARGNF

ARGX

BCRX

BCYC

BEIGF

BGNE

EWTX

IMCR

INCY

INSM

KYMR

MDGL

RARE

REPL

ROIV

RVMDW

Management

Press Releases

Rhythm Pharmaceuticals Announces Appointment of Alastair Garfield, Ph.D., as Chief Scientific Officer

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

Rhythm Pharmaceuticals to Report Second Quarter 2024 Financial Results on Tuesday, August 6, 2024

Rhythm Pharmaceuticals Announces First Patients Dosed in Phase 2 Trial Evaluating Oral MC4R Agonist LB54640 in Hypothalamic Obesity

Rhythm Pharmaceuticals Announces European Commission Expands ▼IMCIVREE® (setmelanotide) Marketing Authorization to include Children as Young as 2 Years Old

Rhythm Pharmaceuticals Reports Second Quarter 2024 Financial Results and Business Update

Rhythm Pharmaceuticals to Present at Wells Fargo Healthcare Conference in September

Rhythm Pharmaceuticals Announces FDA Acceptance for Priority Review of Supplemental New Drug Application for IMCIVREE® (setmelanotide) in Patients as Young as 2 years old

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

Rhythm Pharmaceuticals

Rhythm Pharmaceuticals (RYTM) Forecast

Rhythm Pharmaceuticals (NASDAQ:RYTM) Stock, Quote.Headers.trade-ideas